enVVeno Medical (NVNO)
Market Price (2/21/2026): $11.8 | Market Cap: $6.8 MilSector: Health Care | Industry: Life Sciences Tools & Services
enVVeno Medical (NVNO)
Market Price (2/21/2026): $11.8Market Cap: $6.8 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -442% | Weak multi-year price returns2Y Excs Rtn is -130%, 3Y Excs Rtn is -161% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Vascular Disease Management, and Targeted Therapies. | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 12% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -24 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -326% | ||
| High stock price volatilityVol 12M is 121% | ||
| Key risksNVNO key risks include [1] repeated FDA rejection of its lead product, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -442% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Vascular Disease Management, and Targeted Therapies. |
| Weak multi-year price returns2Y Excs Rtn is -130%, 3Y Excs Rtn is -161% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 12% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -24 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -326% |
| High stock price volatilityVol 12M is 121% |
| Key risksNVNO key risks include [1] repeated FDA rejection of its lead product, Show more. |
Qualitative Assessment
AI Analysis | Feedback
enVVeno Medical (NVNO) stock has lost about 50% since 10/31/2025 because of the following key factors:
1. Unfavorable FDA Appeal Decision for VenoValve. On November 13, 2025, enVVeno Medical announced an unfavorable appeal decision from the U.S. Food & Drug Administration (FDA) regarding its VenoValve product. The FDA determined that the VenoValve "did not meet the standard of reasonable assurance of safety and effectiveness", leading to a 5.16% drop in the stock price upon the announcement. This decision significantly hindered the commercialization pathway for a key product in the company's pipeline.
2. Reverse Stock Split and Subsequent Price Decline. To regain compliance with Nasdaq's minimum bid price requirement, enVVeno Medical announced a 1-for-35 reverse stock split on January 15, 2026. Despite the intent to boost share price and maintain listing, the stock experienced a 13.18% decline following this announcement.
Show more
1. Unfavorable FDA Appeal Decision for VenoValve. On November 13, 2025, enVVeno Medical announced an unfavorable appeal decision from the U.S. Food & Drug Administration (FDA) regarding its VenoValve product. The FDA determined that the VenoValve "did not meet the standard of reasonable assurance of safety and effectiveness", leading to a 5.16% drop in the stock price upon the announcement. This decision significantly hindered the commercialization pathway for a key product in the company's pipeline.
2. Reverse Stock Split and Subsequent Price Decline. To regain compliance with Nasdaq's minimum bid price requirement, enVVeno Medical announced a 1-for-35 reverse stock split on January 15, 2026. Despite the intent to boost share price and maintain listing, the stock experienced a 13.18% decline following this announcement.
Show more
Stock Movement Drivers
Fundamental Drivers
The -52.0% change in NVNO stock from 10/31/2025 to 2/20/2026 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 10312025 | 2202026 | Change |
|---|---|---|---|
| Stock Price ($) | 24.67 | 11.85 | -52.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 1 | 1 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2025 to 2/20/2026| Return | Correlation | |
|---|---|---|
| NVNO | -52.0% | |
| Market (SPY) | 1.1% | 23.8% |
| Sector (XLV) | 8.7% | 15.7% |
Fundamental Drivers
The -92.7% change in NVNO stock from 7/31/2025 to 2/20/2026 was primarily driven by a 1.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312025 | 2202026 | Change |
|---|---|---|---|
| Stock Price ($) | 161.35 | 11.85 | -92.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 1 | 1 | 1.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
7/31/2025 to 2/20/2026| Return | Correlation | |
|---|---|---|
| NVNO | -92.7% | |
| Market (SPY) | 9.4% | 23.3% |
| Sector (XLV) | 20.8% | 8.8% |
Fundamental Drivers
The -89.7% change in NVNO stock from 1/31/2025 to 2/20/2026 was primarily driven by a -20.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312025 | 2202026 | Change |
|---|---|---|---|
| Stock Price ($) | 115.15 | 11.85 | -89.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 1 | -20.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2025 to 2/20/2026| Return | Correlation | |
|---|---|---|
| NVNO | -89.7% | |
| Market (SPY) | 15.6% | 26.1% |
| Sector (XLV) | 8.2% | 12.9% |
Fundamental Drivers
The -94.0% change in NVNO stock from 1/31/2023 to 2/20/2026 was primarily driven by a -44.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312023 | 2202026 | Change |
|---|---|---|---|
| Stock Price ($) | 197.05 | 11.85 | -94.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 1 | -44.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2023 to 2/20/2026| Return | Correlation | |
|---|---|---|
| NVNO | -94.0% | |
| Market (SPY) | 75.9% | 22.5% |
| Sector (XLV) | 23.1% | 11.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| NVNO Return | -24% | -23% | 1% | -41% | -89% | -11% | -97% |
| Peers Return | 17% | -4% | 10% | 14% | 8% | -5% | 47% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 0% | 83% |
Monthly Win Rates [3] | |||||||
| NVNO Win Rate | 33% | 33% | 58% | 33% | 50% | 50% | |
| Peers Win Rate | 50% | 52% | 57% | 52% | 57% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| NVNO Max Drawdown | -42% | -49% | -49% | -52% | -90% | -23% | |
| Peers Max Drawdown | -5% | -26% | -10% | -11% | -10% | -10% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MDT, BSX, BDX, PEN, MMSI.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/20/2026 (YTD)
How Low Can It Go
| Event | NVNO | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -75.5% | -25.4% |
| % Gain to Breakeven | 308.1% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -64.1% | -33.9% |
| % Gain to Breakeven | 178.7% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -92.6% | -19.8% |
| % Gain to Breakeven | 1243.6% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to MDT, BSX, BDX, PEN, MMSI
In The Past
enVVeno Medical's stock fell -75.5% during the 2022 Inflation Shock from a high on 9/27/2021. A -75.5% loss requires a 308.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About enVVeno Medical (NVNO)
enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
AI Analysis | Feedback
Here is one analogy for enVVeno Medical (NVNO):
- Edwards Lifesciences for leg veins. (Similar to how Edwards Lifesciences develops implantable heart valves for cardiovascular issues, enVVeno Medical focuses on developing a novel implantable valve for deep venous disease in the legs.)
AI Analysis | Feedback
- VenoValve: An investigational, gene-modified, allogeneic, off-the-shelf venous valve designed to treat severe chronic venous insufficiency.
AI Analysis | Feedback
enVVeno Medical (NVNO) is a medical device company developing the VENOValve, an investigational device for the treatment of severe venous insufficiency. As a medical device company, its primary sales are to healthcare institutions and providers rather than directly to individuals. Due to the nature of the medical device industry, particularly for companies with products in late-stage development or early commercialization, specific major customer companies are generally not publicly disclosed.
Once commercially available and adopted, enVVeno Medical's customer base would primarily consist of the following categories of healthcare organizations:
- Hospitals: Specifically those with cardiovascular or vascular surgery departments, as the VENOValve is an implantable device requiring a surgical procedure. These institutions purchase medical devices for use by their surgeons and interventionalists.
- Ambulatory Surgical Centers (ASCs): These are outpatient facilities that perform specialized surgical procedures. As procedures become less invasive, suitable cases may transition to ASCs, which would then become purchasers of medical devices.
- Integrated Delivery Networks (IDNs) / Healthcare Systems: Large networks encompassing multiple hospitals, clinics, and physician groups. These systems often have centralized purchasing departments that make decisions on which medical devices to adopt across their network.
AI Analysis | Feedback
nullAI Analysis | Feedback
Robert Berman, Chief Executive Officer, Director
Mr. Berman has served as Chief Executive Officer and a member of the Board of Directors since April 2018, during which time he successfully transitioned enVVeno Medical from a small private company focused on cardiac care to a publicly traded entity focused on venous disease. He has over 25 years of experience in healthcare, finance, acquisitions, marketing, compliance, turnarounds, and the development and licensing of emerging technologies. From September 2012 until July 2017, Mr. Berman served as President, Chief Executive Officer, and a board member of ITUS Corporation (now Anixa Biosciences), where he led its transformation from a flat panel display technology developer into a Nasdaq-listed cancer therapeutics company.
Jennifer Bright, Chief Financial Officer
Ms. Bright joined enVVeno Medical in May 2025 and brings over 25 years of financial and strategic leadership experience. Her background includes roles at commercial-stage medical device and pharmaceutical companies such as Biolase, Spectrum Pharmaceuticals, Apria Healthcare, Smile Brands, and Teleflex Medical. She also possesses technical accounting and auditing experience from her time at PricewaterhouseCoopers LLP. Ms. Bright is a Certified Public Accountant and holds a B.A. degree in Business Administration, Accounting, from the University of Washington.
Marc Glickman, M.D., Senior Vice President and Chief Medical Officer
Dr. Glickman has served as Senior Vice President and Chief Medical Officer since May 2016. In 1981, he initiated a vascular practice in Norfolk, Virginia, and was responsible for establishing the first Vein Center in Virginia and creating a dialysis access center. He was also the director of Vascular Services at Sentara Health Care until his retirement in 2014. Dr. Glickman is board-certified in Vascular Surgery and is a past president of the Vascular Society of the Americas.
Hamed Alavi, Ph. D., Senior Vice President and Chief Technology Officer
Dr. Alavi is an innovative leader recognized for his successful track record in developing advanced medical device technologies across both startup and large corporate settings. Before joining enVVeno Medical, Dr. Alavi held the position of head of engineering at NaviGate Cardiac Structures Inc., a startup focused on developing tricuspid heart valve replacement and delivery system devices.
Andrew Cormack, Chief Commercial Officer
Mr. Cormack serves as the Chief Commercial Officer for enVVeno Medical.
AI Analysis | Feedback
The key risks to enVVeno Medical's business are primarily centered around regulatory hurdles, financial sustainability, and the concentration of its product pipeline.- Regulatory Approval Challenges: The most significant risk stems from the U.S. Food and Drug Administration's (FDA) repeated rejection of the Premarket Approval (PMA) application for enVVeno Medical's lead product, VenoValve, designed to treat severe deep chronic venous insufficiency (CVI). The FDA cited insufficient evidence regarding the benefit-risk profile and safety concerns. A supervisory appeal against the initial rejection was also unsuccessful. This directly impedes the company's ability to commercialize its primary product and generate revenue, leading to substantial delays and uncertainty regarding its market entry.
- Financial Health and Cash Burn: As a late clinical-stage medical device company, enVVeno Medical currently has negligible product revenue. The company maintains a significant quarterly cash burn rate, projected to be around $4-5 million. While the company reported $31.0 million in cash and investments at the end of the third quarter of 2025, sufficient to fund current operations through the second quarter of 2027 (excluding VenoValve commercialization and enVVe IDE study expenses), the ongoing regulatory setbacks for VenoValve prolong the period without revenue generation. This reliance on existing capital without a clear near-term path to product-derived revenue poses a substantial risk to long-term financial viability and may lead to future shareholder dilution.
- Product Pipeline Dependency: enVVeno Medical's business prospects are heavily concentrated on the successful development and approval of its two primary product candidates: VenoValve and its next-generation device, enVVe. With the VenoValve facing significant regulatory obstacles, the company's future now largely depends on enVVe, which is a non-surgical, transcatheter-based replacement venous valve still in earlier stages of development, with human testing yet to commence. This narrow product pipeline means that the failure or significant delay of a single product can have a disproportionately severe impact on the company's overall business and future growth potential.
AI Analysis | Feedback
nullAI Analysis | Feedback
enVVeno Medical (NVNO) has identified addressable markets for its main products, the VenoValve and enVVe, primarily within the United States.
VenoValve
The VenoValve, a surgical replacement venous valve designed to treat severe Chronic Venous Insufficiency (CVI) caused by deep valvular incompetency, targets a substantial addressable market in the U.S.. The total addressable market for the VenoValve is approximately 2.5 million patients in the U.S. alone. Additionally, there are about 600,000 new patients annually in the U.S. for whom the VenoValve could be a treatment option. The U.S. is identified as the company's primary territory for commercialization.
enVVe
The enVVe is a non-surgical, transcatheter-based replacement venous valve. This product is estimated to have an addressable market of approximately 3.5 million patients in the U.S.. The larger market for enVVe is attributed to its potential to include patients with less severe CVI, those with co-morbidities, or individuals for whom an open surgical procedure (like with VenoValve) may present too much risk. It also has the potential to expand the market by enabling treatment by non-surgeons.
AI Analysis | Feedback
enVVeno Medical (NVNO) is a development-stage medical technology company with several key drivers anticipated to fuel future revenue growth over the next 2-3 years. These drivers primarily revolve around the commercialization of its innovative venous disease treatments and strategic market penetration. Here are the expected drivers of future revenue growth for enVVeno Medical:- Commercialization and Adoption of VenoValve: The company's lead product, VenoValve, a surgical replacement venous valve for deep venous Chronic Venous Insufficiency (CVI), is a primary revenue driver. enVVeno Medical submitted a PMA application for VenoValve to the FDA in Q4 2024 and expects to transition from development to commercialization for this product in early 2025. The VenoValve targets a significant U.S. market of approximately 2.5 million patients, with an estimated 600,000 new patients annually, and could command a price between $20,000 and $25,000 per device.
- Advancement and Commercialization of enVVe: enVVeno Medical is also developing enVVe, a non-surgical, transcatheter-based replacement venous valve. The company successfully completed a pre-clinical GLP study for enVVe and plans to submit an Investigational Device Exemption (IDE) application to the FDA by mid-2025, anticipating a pivotal trial approval in early 2025. This product has the potential to expand the total addressable market to include patients with less severe disease, co-morbidities, or those for whom open surgical procedures are too risky. It may also enable non-surgeons to perform the procedure, significantly increasing the number of potential treatments.
- Market Expansion and Increased Adoption of Innovative Devices: The company's strategic focus on developing advanced medical devices for venous and lymphatic diseases, coupled with expanding its market reach, is expected to drive substantial revenue growth. Analysts project an 87.3% annual revenue growth rate as the company expands its portfolio and market presence, driven by increased adoption of its innovative medical devices. The estimated patient population in the U.S. with severe CVI caused by malfunctioning valves ranges from 2.5 million to 3.5 million, representing a significant market opportunity for enVVeno's solutions.
- Strategic Initiatives and Competitive Advantages: enVVeno Medical aims to be a leader in therapies for venous conditions that have historically been challenging to manage with conventional treatments. The innovative nature of its products, particularly the VenoValve's Breakthrough Device Designation and Investigational Device Exemption, positions it with a strong competitive advantage due to a lack of direct competition in case of approval. The company's engagement with leading vascular specialists and academic institutions further supports the adoption and integration of its technologies into clinical practice.
AI Analysis | Feedback
Share Issuance
- In October 2025, enVVeno Medical initiated an At-the-Market (ATM) Offering Agreement to potentially sell up to $50,000,000 of common stock.
- In early 2024, the company completed a private placement which raised $28 million, with participation from institutional investors.
- As of October 29, 2025, the number of common shares outstanding was 20,216,176.
Inbound Investments
- The company reported $31.0 million in cash and investments as of September 30, 2025, which is anticipated to fund operations through the second quarter of 2027, excluding VenoValve commercialization and enVVe IDE study costs.
- As of June 30, 2025, enVVeno Medical held $35.1 million in cash and investments, projected to fund operations through the third quarter of 2026.
- A $28 million private placement led by institutional investors, including Perceptive Advisors and Nantahala Capital, was completed in early 2024.
Capital Expenditures
- Over the last 12 months, capital expenditures totaled -$9,000.
- Modest increases in property and equipment purchases are expected for the SAVVE study continuation, VenoValve commercialization planning, and enVVe development.
- The company's cash burn rate was $4.2 million in Q3 2025 and $3.8 million in Q2 2025, aligning with a projected quarterly range of $4-5 million, with an anticipated increase upon VenoValve commercialization.
Trade Ideas
Select ideas related to NVNO.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 01302026 | VEEV | Veeva Systems | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -14.6% | -14.6% | -15.7% |
| 01162026 | BIIB | Biogen | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 19.5% | 19.5% | 0.0% |
| 01162026 | BMRN | BioMarin Pharmaceutical | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 9.7% | 9.7% | 0.0% |
| 01162026 | DOCS | Doximity | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -39.4% | -39.4% | -40.1% |
| 01022026 | CORT | Corcept Therapeutics | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | 4.6% | 4.6% | -9.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 89.53 |
| Mkt Cap | 33.1 |
| Rev LTM | 10,414 |
| Op Inc LTM | 1,638 |
| FCF LTM | 1,417 |
| FCF 3Y Avg | 1,263 |
| CFO LTM | 1,831 |
| CFO 3Y Avg | 1,751 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 11.4% |
| Rev Chg 3Y Avg | 9.2% |
| Rev Chg Q | 13.0% |
| QoQ Delta Rev Chg LTM | 3.1% |
| Op Mgn LTM | 14.2% |
| Op Mgn 3Y Avg | 13.3% |
| QoQ Delta Op Mgn LTM | 0.5% |
| CFO/Rev LTM | 18.1% |
| CFO/Rev 3Y Avg | 16.9% |
| FCF/Rev LTM | 13.8% |
| FCF/Rev 3Y Avg | 13.3% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 33.1 |
| P/S | 3.6 |
| P/EBIT | 23.7 |
| P/E | 34.9 |
| P/CFO | 17.8 |
| Total Yield | 2.5% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 2.4% |
| D/E | 0.1 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -4.3% |
| 3M Rtn | -3.4% |
| 6M Rtn | -7.1% |
| 12M Rtn | -19.5% |
| 3Y Rtn | 21.6% |
| 1M Excs Rtn | -4.8% |
| 3M Excs Rtn | -7.1% |
| 6M Excs Rtn | -13.9% |
| 12M Excs Rtn | -32.2% |
| 3Y Excs Rtn | -44.2% |
Price Behavior
Price Behavior
| Market Price | $11.85 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 05/31/2018 | |
| Distance from 52W High | -93.6% | |
| 50 Days | 200 Days | |
| DMA Price | $11.17 | $66.44 |
| DMA Trend | down | down |
| Distance from DMA | 6.1% | -82.2% |
| 3M | 1YR | |
| Volatility | 111.6% | 120.8% |
| Downside Capture | 100.82 | 455.66 |
| Upside Capture | 92.98 | 154.67 |
| Correlation (SPY) | 17.0% | 25.9% |
NVNO Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -1.74 | -0.25 | 1.83 | 3.01 | 1.54 | 1.32 |
| Up Beta | -3.49 | -0.16 | 1.80 | 1.91 | 0.95 | 1.17 |
| Down Beta | 1.83 | 1.36 | 0.69 | 2.20 | 1.15 | 1.16 |
| Up Capture | -266% | -175% | 19% | 19% | 163% | 69% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 8 | 20 | 30 | 59 | 120 | 345 |
| Down Capture | -654% | -54% | 368% | 390% | 172% | 112% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 11 | 20 | 30 | 64 | 127 | 389 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NVNO | |
|---|---|---|---|---|
| NVNO | -90.7% | 120.8% | -1.13 | - |
| Sector ETF (XLV) | 8.6% | 17.3% | 0.32 | 13.0% |
| Equity (SPY) | 13.5% | 19.4% | 0.53 | 26.3% |
| Gold (GLD) | 74.5% | 25.6% | 2.15 | 2.2% |
| Commodities (DBC) | 7.2% | 16.9% | 0.25 | 7.7% |
| Real Estate (VNQ) | 7.1% | 16.7% | 0.24 | 15.8% |
| Bitcoin (BTCUSD) | -30.6% | 44.9% | -0.68 | 25.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NVNO | |
|---|---|---|---|---|
| NVNO | -46.3% | 81.0% | -0.33 | - |
| Sector ETF (XLV) | 7.6% | 14.5% | 0.34 | 14.5% |
| Equity (SPY) | 13.4% | 17.0% | 0.62 | 23.2% |
| Gold (GLD) | 22.6% | 17.1% | 1.08 | 4.3% |
| Commodities (DBC) | 10.9% | 19.0% | 0.46 | 4.5% |
| Real Estate (VNQ) | 5.0% | 18.8% | 0.17 | 16.2% |
| Bitcoin (BTCUSD) | 7.2% | 57.1% | 0.35 | 14.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NVNO | |
|---|---|---|---|---|
| NVNO | -44.9% | 94.5% | -0.35 | - |
| Sector ETF (XLV) | 11.3% | 16.5% | 0.57 | 15.3% |
| Equity (SPY) | 16.1% | 17.9% | 0.77 | 20.4% |
| Gold (GLD) | 14.8% | 15.6% | 0.79 | 1.9% |
| Commodities (DBC) | 8.6% | 17.6% | 0.40 | 6.5% |
| Real Estate (VNQ) | 7.0% | 20.7% | 0.30 | 16.7% |
| Bitcoin (BTCUSD) | 67.8% | 66.7% | 1.07 | 11.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/4/2026 | -8.2% | ||
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 1 | 0 | 0 |
| Median Positive | |||
| Median Negative | -8.2% | ||
| Max Positive | |||
| Max Negative | -8.2% | ||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 10/30/2025 | 10-Q |
| 06/30/2025 | 07/31/2025 | 10-Q |
| 03/31/2025 | 04/30/2025 | 10-Q |
| 12/31/2024 | 02/28/2025 | 10-K |
| 09/30/2024 | 10/31/2024 | 10-Q |
| 06/30/2024 | 07/31/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/29/2024 | 10-K |
| 09/30/2023 | 10/26/2023 | 10-Q |
| 06/30/2023 | 07/31/2023 | 10-Q |
| 03/31/2023 | 04/28/2023 | 10-Q |
| 12/31/2022 | 03/02/2023 | 10-K |
| 09/30/2022 | 10/27/2022 | 10-Q |
| 06/30/2022 | 08/03/2022 | 10-Q |
| 03/31/2022 | 04/29/2022 | 10-Q |
| 12/31/2021 | 03/28/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Duhay, Francis | Direct | Sell | 12122025 | 0.36 | 4,900 | 1,742 | 32,909 | Form | |
| 2 | Duhay, Francis | Direct | Sell | 9172025 | 0.83 | 4,900 | 4,067 | 80,879 | Form | |
| 3 | Duhay, Francis | Direct | Buy | 1032025 | 3.07 | 81,433 | 249,999 | 314,196 | Form | |
| 4 | Gray, Robert | Direct | Buy | 1022025 | 2.94 | 3,500 | 10,290 | 32,796 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.